Mesalazin Orion

Mesalazine, the active ingredient in Mesalazin Orion, is a aminosalicylate presented as an oral dosage form for oral use. It treats ulcerative colitis and Crohn's disease by reducing intestinal inflammation in adult patients.

GNH USA supplies Mesalazin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazin Orion is used in the management of inflammatory bowel disease, targeting mucosal inflammation.

- Ulcerative colitis: induces remission and maintains disease control by decreasing colonic inflammation. - Crohn's disease: reduces intestinal lesions and symptoms, supporting long‑term disease management. - Maintenance therapy: helps prevent relapse after induction of remission in IBD patients.

Mesalazin Orion may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Abdominal pain: cramping or discomfort in the gut. - Headache: transient mild headaches. - Flatulence: increased intestinal gas. - Rash: skin irritation or mild erythema. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, swelling, or difficulty breathing. - Blood disorders: neutropenia or agranulocytosis. - Hepatic enzyme elevation: signs of liver injury. - Pancreatitis: abdominal pain with elevated enzymes. - Nephritis: kidney inflammation or dysfunction. - Severe colitis flare: worsening of underlying disease.

Before prescribing Mesalazin Orion, clinicians should consider several safety measures.

- Renal function monitoring: assess kidney status regularly. - Hepatic function monitoring: check liver enzymes during therapy. - Disease severity assessment: ensure appropriate indication before initiation. - Hypersensitivity avoidance: do not use in patients with known mesalazine allergy. - Pregnancy caution: evaluate risk‑benefit as safety data are limited. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mesalazin Orion can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Azathioprine: increased risk of bone marrow suppression. - Warfarin: potentiation of anticoagulant effect, raising INR. - Sulfasalazine: additive toxicity, especially to kidneys.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy. - Methotrexate: increased hepatic toxicity risk.